The Bulk Drug Manufacturers Association (BDMA) celebrated a significant milestone with the successful completion of the first batch of training at its Technology and Training Centre, located in Jeedimetla Industrial Estate. This initiative is aimed at providing specialized training to develop a skilled workforce for the bulk drug and pharmaceutical industries, which are vital to India’s economy and global pharmaceutical standing.
The graduation ceremony, held on September 12th, 2024, was presided over by Dr. B. Partha Saradhi Reddy, Chairman of the Hetero Group of Companies and Honorable Rajya Sabha Member, who served as the Chief Guest. Dr. A. Ramkishan, Deputy Drugs Controller (India), graced the occasion as the Guest of Honor. Both distinguished guests highlighted the importance of skill development in the pharmaceutical sector, particularly in bulk drug manufacturing, which plays a critical role in the supply of Active Pharmaceutical Ingredients (APIs) globally.
During the event, Dr. Reddy handed out certificates to the successful candidates, marking the end of their training journey. He emphasized the critical role the newly skilled workforce would play in enhancing the capabilities of the bulk drug industry. He also praised the BDMA Technology and Training Centre for addressing the industry’s pressing need for qualified personnel. “We are building a stronger foundation for the pharmaceutical sector, and skilled manpower is the key to maintaining global leadership in this industry,” Dr. Reddy remarked.
The BDMA’s training initiative has garnered positive responses from industry stakeholders, with many pharmaceutical companies expressing interest in hiring the freshly trained graduates. Notably, the Hetero Group itself has offered employment to around 45 trainees from the first and second batches, highlighting the demand for skilled professionals in the sector.
The BDMA Technology and Training Centre was established to address the skill gap in the pharmaceutical sector, focusing on developing expertise in areas such as bulk drug manufacturing, compliance, and quality assurance. The training is designed to equip candidates with the necessary technical knowledge and practical skills required to meet the growing demands of the industry. With India being one of the largest producers of generic drugs and APIs, such initiatives are crucial for maintaining and expanding the country’s global footprint in the pharmaceutical industry.
The event was also attended by several notable figures, including members of the BDMA Executive Committee and representatives from Pharmapatashala, the training implementation partner for the BDMA Technology and Training Centre. These stakeholders have played an integral role in shaping the curriculum and ensuring that the training meets industry standards.
As the first batch of trainees embarks on their professional journeys, the success of the BDMA Technology and Training Centre marks a promising start for future batches. With the growing demand for skilled workers in the pharmaceutical sector, the Centre is set to become a cornerstone in fostering talent for the industry. Plans for expanding the training program and increasing the intake of future batches are already underway, ensuring a steady supply of skilled professionals for the bulk drug and pharmaceutical industries in India.
The BDMA’s efforts align with the broader goals of enhancing India’s position as a leader in global pharmaceutical manufacturing and export, contributing to both the national economy and healthcare worldwide.
